Top Page
Cronos Australia Ltd.
(Sydney:VIT)
Cronos Australia Ltd. (VIT) vs. iShares MSCI Australia ETF (EWA)
Cronos Australia Ltd. Business Overview & Revenue Model
Cronos Australia Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 124.04M | 124.04M | 123.87M | 117.34M | 66.99M | 21.71M |
| Gross Profit | 33.75M | 33.75M | 34.22M | 25.96M | 25.43M | 3.19M |
| EBITDA | 5.64M | 5.64M | 7.08M | 21.08M | 10.87M | 2.12M |
| Net Income | 3.32M | 3.32M | 3.51M | 13.81M | 6.05M | -4.05M |
Balance Sheet | ||||||
| Total Assets | 75.49M | 75.49M | 71.28M | 46.90M | 42.87M | 12.69M |
| Cash, Cash Equivalents and Short-Term Investments | 7.58M | 7.58M | 11.35M | 18.85M | 16.08M | 9.47M |
| Total Debt | 11.97M | 11.97M | 11.02M | 1.71M | 5.06M | 718.02K |
| Total Liabilities | 27.89M | 27.89M | 32.84M | 11.99M | 16.79M | 3.47M |
| Stockholders Equity | 48.20M | 48.20M | 38.78M | 34.98M | 26.10M | 9.30M |
Cash Flow | ||||||
| Free Cash Flow | 2.58M | 2.58M | 6.21M | 8.78M | 13.13M | 1.01M |
| Operating Cash Flow | 2.67M | 2.67M | 7.00M | 9.71M | 13.50M | 1.07M |
| Investing Cash Flow | -13.87M | -13.87M | -13.20M | -837.72K | 2.00M | -160.69K |
| Financing Cash Flow | 7.43M | 7.43M | -1.30M | -6.10M | -1.50M | -262.03K |
Cronos Australia Ltd. Technical Analysis
Cronos Australia Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | AU$41.75M | 11.67 | 7.64% | 3.17% | 0.13% | -12.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $3.32M | -1.30 | -26.84% | ― | 36.60% | 85.28% | |
41 Neutral | AU$19.03M | -1.28 | ― | ― | -47.30% | 82.53% | |
38 Underperform | AU$9.13M | ― | -401.36% | ― | -26.49% | 61.72% |
Cronos Australia Ltd. Corporate Events
Vitura Health Limited announced the resignation of its Chief Financial Officer and Company Secretary, Tom Howitt, effective January 2026. Howitt, who has been with the company since its inception, played a crucial role in its ASX listing and strategic acquisitions. His departure marks a significant change in the company’s leadership, with recruitment for his replacement already underway.
Vitura Health Limited has announced its Annual General Meeting scheduled for November 26, 2025, which will be held in a hybrid format allowing both in-person and online participation. This meeting is crucial for shareholders as it provides an opportunity to vote on resolutions and engage with the company’s management, potentially impacting the company’s future strategies and stakeholder relations.
Vitura Health Limited has released its 2025 Annual Report, emphasizing its commitment to building a future-focused healthcare network. The report highlights the company’s dedication to reconciliation with Aboriginal communities and acknowledges the Traditional Owners of the lands on which it operates. This announcement underscores Vitura Health’s strategic focus on strengthening relationships and fostering inclusivity, which is likely to enhance its industry positioning and stakeholder engagement.
Vitura Health Limited has announced an update regarding its dividend distribution, providing details on the final Dividend Reinvestment Plan (DRP) allocation price and the number of shares to be issued. This update is part of the company’s ongoing financial management strategy, which may impact shareholder value and market perception as it relates to the financial period ending June 30, 2025.
Vitura Health Limited has announced the scheduling of its 2025 Annual General Meeting for November 26, 2025. The meeting will cover various business items, and nominations for director elections are due by October 1, 2025. This announcement is part of Vitura’s ongoing efforts to maintain transparency and engage with its shareholders, reflecting its strategic focus on expanding its digital health operations and enhancing its market position in the medicinal cannabis and psychedelic sectors.
Cronos Australia Ltd. has announced a change in the substantial holding of Guy Rothwell Headley in Vitura Health Limited. The change, effective from September 5, 2025, results from an off-market transfer due to a financial agreement, reducing Headley’s voting power from 15.26% to 7.57%. This adjustment in holdings may impact the company’s governance and influence within Vitura Health Limited.
Vitura Health Limited has announced an investor webinar to present its FY2025 financial results, highlighting its strategic initiatives and operational advancements. The company’s focus on integrating digital health solutions, such as the Canview platform and telehealth services, positions it as a leader in the Australian healthcare market, with significant opportunities in the distribution of medicinal cannabis and psychedelic products.
The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has announced a dividend distribution for its ordinary fully paid shares. The dividend amount is set at AUD 0.002 per share, with key dates including an ex-date of September 5, 2025, a record date of September 8, 2025, and a payment date of September 30, 2025. This announcement reflects the company’s financial performance for the period ending June 30, 2025, and provides shareholders with a return on their investment.
The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has announced its third fully franked dividend of 0.2 cents per share, totaling approximately $1.32 million. The company reported revenues of $124 million and a net profit after tax of $3.1 million for FY2025, marking it as a profitable player in the medicinal cannabis industry. Vitura is also offering a Dividend Reinvestment Plan, allowing shareholders to acquire additional shares at a discount, reflecting its commitment to enhancing shareholder value and continuing its growth strategy.
The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited reported its FY2025 financial results, highlighting a modest revenue increase to $124.04 million and a significant 23.5% rise in EBITDA to $7.63 million. Despite facing industry-wide price declines in medicinal cannabis, Vitura’s strategic acquisitions and operational efficiencies contributed to its growth. The company expanded its patient base through acquisitions such as Candor Medical and Releaf Group, and saw substantial growth in its telehealth business, Doctors on Demand. However, net profit after tax decreased by 5.8% due to higher amortization and interest costs. Vitura’s strategic repositioning and focus on cost management underscore its resilience in a competitive market.
The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has released its corporate governance statement for the financial year ending June 30, 2025, which adheres to the ASX Corporate Governance Council’s principles and recommendations. The statement, approved by the board, is included in the company’s financial report and outlines the extent of compliance with governance recommendations, providing transparency and accountability to stakeholders.
The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Cronos Australia Ltd. reported a slight increase in total revenues to $124 million for the year ended 30 June 2025, despite a decrease in net profit due to industry-wide gross margin pressures and increased expenses. The company experienced a notable rise in medical consultation and service fees, largely attributed to the acquisition of Candor Medical and the continued growth of Doctors on Demand. While the medicinal cannabis industry faced challenges such as price compression, Cronos Australia’s strategic investments in platforms like Canview and Doctors on Demand are expected to drive future growth. The company also announced a dividend payment and highlighted a decrease in total liabilities and expenses, reflecting improved financial management.
The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has announced the issuance of unquoted equity securities, including 12,814,845 unquoted options and 6,593,145 performance rights, effective from August 1, 2025. This move is likely aimed at enhancing the company’s capital structure and providing incentives for performance, which could have implications for its market positioning and stakeholder interests.
The most recent analyst rating on (AU:VIT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.